Health Canada has approved new health claims for Sabinsa’s Curcumin C3 Complex and Curcumin C3 Reduct.
Photo © iStockphoto.com/Elzbieta Sekowska
Two of Sabinsa’s (East Windsor, NJ) curcumin ingredients have received approval for new health claims by Health Canada. Supplement products containing Sabinsa’s Curcumin C3 Complex and Curcumin C3 Reduct can now carry additional claims for support of healthy serum triglyceride levels and for providing antioxidants, respectively, in Canada.
The first new health claim approved by Health Canada, “supports healthy serum triglyceride levels, provides antioxidant,” applies to the combination of 500 mg of Curcumin C3 Complex and 5 mg of Sabinsa’s BioPerine patented black pepper extract in a twice-daily dose. Sabinsa notes that the claim is backed by a clinical trial showing supplementation with Curcumin C3 Complex significantly reduced serum triglyceride concentrations in obese subjects.
The other new health claim, which applies to Sabinsa’s relatively new Curcumin C3 Reduct, is the “first health claim for a curcumin metabolite” to be approved by Health Canada, according to Sabinsa. Curcumin C3 Reduct is standardized to 95% tetrahydrocucuminoids, the most active metabolite of curcuminoids. The new Canadian health claim for Curcumin C3 Reduct reads, “provides antioxidants,” and applies to 100 mg dosages of Curcumin C2 Reduct taken twice daily.
“As the science on our natural products is increasing, we are determined to gain approval for new health claims supported by clinical studies for the Canadian market, where premarket approval for the health claims is required, thus validating our science,” said Shaheen Majeed, marketing director for Sabinsa.
Read more:
Sabinsa Europe Signs Curcumin Supply Agreement with Healthspan Limited
Turmeric Rising: Turmeric and Curcumin Research Is Hot
Radiocarbon Provides “Conclusive Test” for Detecting Synthetic Curcumin, Sabinsa Says
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.